Chronic Rhinitis Clinical Trial
— FROSTOfficial title:
Clinical Evaluation of Safety and Efficacy for the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis
NCT number | NCT03181594 |
Other study ID # | CT-0003 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 2, 2017 |
Est. completion date | April 6, 2020 |
Verified date | February 2021 |
Source | Arrinex, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A multi-center, prospective, non-randomized, interventional clinical trial to assess the safety and effectiveness of the ClariFix™ device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.
Status | Completed |
Enrollment | 100 |
Est. completion date | April 6, 2020 |
Est. primary completion date | July 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is >21 years of age 2. Subject has moderate to severe symptoms of rhinorrhea (individual symptom rating of 2 or 3), mild to severe symptoms of congestion (individual symptom rating of 1, 2 or 3) and a minimum TNSS score of 4 (out of 12) at the time of the treatment visit, which have been present for > 6 months. 3. Subject has had documented allergy test within the last 10 years that defines whether or not subject has allergies to perennial and seasonal allergens or is willing to have one performed prior to study exit. 4. Subject has been dissatisfied with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief by the subject's assessment. 5. Subject has signed IRB-approved informed consent form Exclusion Criteria: 1. Subject has clinically significant anatomic obstructions that in the investigator's opinion limit access to the posterior nose, including but not limited to septal deviation or perforation, nasal polyps, sinonasal tumor. 2. Subject has had any prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose. 3. Subject has active nasal or sinus infection. 4. Subject has moderate to severe ocular symptoms. 5. Subject has a history of nosebleeds in the past 3 months. 6. Subject has a history of rhinitis medicamentosa. 7. Subject has had prior head or neck irradiation 8. Subject has active coagulation disorder or is receiving anti-coagulants which cannot be safely stopped for 4 weeks (excluding aspirin). 9. Subject is pregnant. 10. Subject is participating in another clinical research study. 11. Subject has an allergy or intolerance to anesthetic agent. 12. Subject has cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and/or, open and/or infected wounds at or near the target tissue. 13. Any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk. |
Country | Name | City | State |
---|---|---|---|
United States | Bethlehem Ear, Nose, and Throat | Bethlehem | Pennsylvania |
United States | Ear, Nose, and Throat Associates of South Florida | Boca Raton | Florida |
United States | California Sleep Institute | East Palo Alto | California |
United States | EVMS Otolaryngology | Norfolk | Virginia |
United States | Sacramento Ear, Nose, and Throat | Sacramento | California |
United States | San Francisco Otolaryngology Medical Group | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Arrinex, Inc. |
United States,
Chang MT, Song S, Hwang PH. Cryosurgical ablation for treatment of rhinitis: A prospective multicenter study. Laryngoscope. 2020 Aug;130(8):1877-1884. doi: 10.1002/lary.28301. Epub 2019 Sep 30. — View Citation
Ow RA, O'Malley EM, Han JK, Lam KK, Yen DM. Cryosurgical Ablation for Treatment of Rhinitis: Two-Year Results of a Prospective Multicenter Study. Laryngoscope. 2021 Feb 22. doi: 10.1002/lary.29453. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change From Baseline in Symptom Severity | Median change in nasal symptoms using the 4-symptom rTNSS (reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual patient-rated symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, and 3=Severe. The rTNSS has a possible score of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 24 hours. A change of 1 point or more is considered the minimum clinically important difference. | 1, 3, 6, 9, 12, 15, 18, 21, and 24 months post procedure | |
Primary | Change From Baseline in Symptom Severity | Effectiveness will be assessed by the mean change in nasal symptoms using the 4-symptom rTNSS (reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual patient-rated symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, and 3=Severe. The rTNSS has a possible score of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 24 hours. A change of 1 or more is considered the minimum clinically important difference. | 90 days post treatment | |
Primary | Device- and/or Procedure-related Serious Adverse Events | Safety will be evaluated based on the frequency of device- and/or procedure-related serious adverse events | 90 days post treatment | |
Secondary | Change From Baseline in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) | The RQLQ is a validated quality of life questionnaire that evaluates functional problems associated with rhinitis. The questionnaire assess 7 domains: activities, sleep, nose symptoms, eye symptoms, non nose/eye symptoms, practical problems, and emotional function. Each question is scores on a 7-point scale (0=not impaired at all, 6=severely impaired). A domain and total scores are based on the mean of all answered items in that domain resulting in domain or total scores ranging from 0 to 6. An average change on 0.5 or more is considered a minimal clinically important difference. | 90 days post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05331222 -
Proof-of-Concept Interventional Study With a Nasal Spray of JT-1 in Patients With Chronic Rhinitis or Chronic Sinusitis
|
N/A | |
Active, not recruiting |
NCT05591989 -
Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)
|
N/A | |
Active, not recruiting |
NCT04614324 -
A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)
|
N/A | |
Recruiting |
NCT01546662 -
A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.
|
N/A | |
Terminated |
NCT00737906 -
Surgical Reduction of the Inferior Turbinates for Nasal Obstruction
|
Phase 4 | |
Completed |
NCT03727347 -
Posterior Nasal Nerve (PNN) Rhinitis Study
|
N/A | |
Recruiting |
NCT06128200 -
NEUROMARK Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT04154605 -
ClariFix Rhinitis RCT
|
N/A | |
Recruiting |
NCT05626621 -
Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis
|
Phase 4 | |
Completed |
NCT04684875 -
Quality of Life Impact of Chronic Rhinitis Treatment With Aerin Medical Device
|
||
Completed |
NCT01364467 -
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study
|
Phase 2 | |
Completed |
NCT05324397 -
Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis (CLARITY)
|
N/A | |
Completed |
NCT03739216 -
Registry of Subject Treated With ClariFix
|
||
Recruiting |
NCT05937308 -
NEUROMARK Registry Study
|
N/A | |
Active, not recruiting |
NCT04533438 -
RhinAer Procedure for Treatment of Chronic Rhinitis Study
|
N/A | |
Completed |
NCT04375293 -
Characterisation of the Nasal Microbiome in Patients With N-ERD
|
N/A | |
Completed |
NCT03893227 -
Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation
|
||
Terminated |
NCT00584662 -
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
|
N/A | |
Recruiting |
NCT05648565 -
Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis
|
N/A | |
Completed |
NCT04769596 -
Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis
|
N/A |